American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

CytoDyn Inc. (CYDY)

$0.23 -8.28% OTC: CYDY · 15-min delayed

VANCOUVER, Washington
Public · OTC: CYDY

Visit website Follow

$0Revenue · FY2023

$3.7MNet income

CYDYOTC

About CytoDyn Inc.

CYTODYN INC

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · OTC: CYDY
Headquarters: VANCOUVER, Washington
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 529900Q4JAVBX3H8RF98

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: CYDY OTC
SEC CIK: 1175680
LEI: 529900Q4JAVBX3H8RF98
EIN: 753056237
SIC: 2834 Pharmaceutical Preparations

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show CytoDyn Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/cytodyn-inc/"><img src="https://americancompanies.com/badge/cytodyn-inc.svg" alt="CytoDyn Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow CytoDyn Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2023: $0
Net income: $3.7M
Total assets: $18.0M

Source: SEC EDGAR · updated Jun 7, 2026

OTC: CYDY

$0.23 -8.28%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.19 $0.37

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

CytoDyn Inc. (CYDY) Stock Price

Profitable — net income of $3.7M in FY2023.
Trading 38% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review CytoDyn Inc..

Write a review

Newsroom

News about CytoDyn Inc.

CytoDyn Announces Settlement with Amarex Clinical Research LLC - GlobeNewswire GlobeNewswire Inc. · 2024-07-09 · positive CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024 GlobeNewswire Inc. · 2024-06-27 CytoDyn to Host Webcast to Provide Company Update GlobeNewswire Inc. · 2024-05-28 May 2024 Letter to Shareholders GlobeNewswire Inc. · 2024-05-16

News & sentiment via Polygon.io

FAQ

CytoDyn Inc.: frequently asked questions

Is CytoDyn Inc. an American company?

CytoDyn Inc. is a US-based company headquartered in Vancouver, Washington, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is CytoDyn Inc. headquartered?

CytoDyn Inc. is headquartered in Vancouver, Washington, United States.

Is CytoDyn Inc. publicly traded?

Yes — CytoDyn Inc. is a publicly traded company. Its stock trades under the ticker symbol CYDY on the OTC.

What does CytoDyn Inc. do?

CytoDyn Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore